The homeobox transcription factor CDX2 plays an important role in embryonic development and regulates the proliferation and differentiation of intestinal epithelial cells in the adult. We have found that CDX2 is expressed in leukemic cells of 90% of patients with acute myeloid leukemia (AML) but not in hematopoietic stem and progenitor cells derived from normal individuals. Stable knockdown of CDX2 expression by RNA interference inhibited the proliferation of various human AML cell lines and strongly reduced their clonogenic potential in vitro. Primary murine hematopoietic progenitor cells transduced with Cdx2 acquired serial replating activity, were able to be continuously propagated in liquid culture, generated fully penetrant and transplantable AML in BM transplant recipients, and displayed dysregulated expression of Hox family members in vitro and in vivo. These results demonstrate that aberrant expression of the developmental regulatory gene CDX2 in the adult hematopoietic compartment is a frequent event in the pathogenesis of AML; suggest a role for CDX2 as part of a common effector pathway that promotes the proliferative capacity and self-renewal potential of myeloid progenitor cells; and support the hypothesis that CDX2 is responsible, in part, for the altered HOX gene expression that is observed in most cases of AML.
Introduction
The caudal-type homeobox gene Cdx2 encodes a transcription factor that contributes to embryonic organogenesis and early hematopoietic development in vertebrate species (1-4). Of note, previous studies using genetic approaches have shown that the developmental effects of Cdx2, like those of other Cdx family members, are mediated through regulation of Hox gene expression and that Cdx proteins can act directly on Hox gene regulatory elements (5) (6) (7) . Furthermore, Cdx2 is essential for establishment and function of the trophectoderm lineage at implantation (8) (9) (10) . In mice, expression of Cdx2 is limited almost exclusively to the endoderm of the primitive gut by E12.5, and this pattern is maintained throughout life, with highest expression levels in the distal intestine and the proximal colon (11, 12) . Likewise, expression of human CDX2 has only been detected in intestinal epithelial cells (11, 12) .
Considerable evidence suggests that abnormalities of CDX2 are relevant to human gastrointestinal malignancies. Gene targeting studies in mice and the analysis of human colorectal cancer specimens have shown that CDX2 functions as a tumor suppressor in the colon (13) (14) (15) (16) (17) (18) , whereas ectopic CDX2 expression is involved in the development of precancerous intestinal metaplasia in the stomach and esophagus (19) (20) (21) (22) .
Dysregulated CDX2 expression has only rarely been attributed to cancers that occur outside the gastrointestinal tract. Chase et al. described a fusion between CDX2 and the TEL gene at chromosome 12p13 in a single patient with acute myeloid leukemia (AML) and t(12;13)(p13;q12) and found that both the chimeric TEL-CDX2 fusion transcript and normal CDX2 transcripts were detectable in cDNA from this patient (23) . Rawat et al. subsequently showed that ectopic expression of Cdx2, but not expression of the TEL-CDX2 fusion gene, caused AML in a murine BM transplantation model of t(12;13)-positive AML (24) . In the former study, conventional RT-PCR analysis detected CDX2 mRNA in 1 of 10 patients in the blast phase of chronic myeloid leukemia (CML-BP) who did not have cytogenetic evidence of chromosome 13 abnormalities but did not identify aberrant CDX2 expression in 10 AML patients without aberrations involving chromosome 13 (23) . Thus, it remains unclear to what extent ectopic expression of CDX2 has a more general role in myeloid leukemogenesis.
Using array-based comparative genomic hybridization (aCGH) and FISH, we recently demonstrated high-level amplification of the CDX2 locus in a subset of AML patients with complex karyotypes lacking cytogenetic abnormalities involving chromosome 13 (25) . This observation prompted us to systematically analyze the expression of CDX2 in a large cohort of patients with myeloid leukemias by real-time quantitative PCR (RQ-PCR). We detected CDX2 expression in 90% of patients with AML, in patients with high-risk myelodysplastic syndrome (MDS) or advanced-stage CML, and in several AML cell lines, but not in hematopoietic stem and progenitor cells derived from normal individuals. We explored the functional relevance of aberrant CDX2 expression in AML by RNA interference-mediated (RNAi-mediated) knockdown of CDX2 in AML cell lines, by ectopic expression of Cdx2 in primary murine hematopoietic progenitors, and in a murine model of Cdx2-induced AML.
Results
Aberrant CDX2 expression in AML. CDX2 transcripts were detectable in BM mononuclear cells (BMMCs) or PBMCs from 153 (90%) of 170 patients with AML ( Figure 1 ). The median expression level for all samples was 508 (range, 0-88,020), and there was a statistically significant difference between different cytogenetic subgroups (P = 0.02; Table 1 ). The highest CDX2 expression levels were present in patients with t(9;11)(p22;q23), followed by those with normal karyotype, t(15;17)(q22;q11~21), t(8;21)(q22;q22), inv(16)(p13q22), other chromosome aberrations, and complex karyotype, defined as 3 or more cytogenetic abnormalities in the absence of t(8;21), inv (16) , t(15;17), or t(11q23). In 3 of the 30 patients with complex karyotypes, we previously found high-level amplification of the CDX2 locus, as assessed by aCGH and FISH (25) , and each of these 3 patients expressed high levels of CDX2 transcripts (expression levels, 1,650; 2,063; and 22,477, respectively). In comparison, BMMCs (n = 10), CD34 + cells (n = 3), HSCs (n = 3), common myeloid progenitors (CMPs; n = 3), granulocyte-macrophage progenitors (GMPs; n = 3), and megakaryocyte-erythroid progenitors (MEPs; n = 3) derived from normal individuals showed no detectable CDX2 expression by RQ-PCR (Figure 1) .
In 2 AML patients, CDX2 expression levels were analyzed at different time points. Patient 1, who had inv(16)-positive AML, achieved complete remission (CR) after the first of 2 courses of induction chemotherapy according to the ICE protocol (12 mg/m 2 idarubicin on days 1, 3, and 5; 100 mg/m 2 cytarabine continuously on days 1-7; 100 mg/m 2 etoposide on days 1-3) and remained disease free after 1 course of consolidation chemotherapy with HAM (3 g/m 2 cytarabine every 12 hours on days 1 through 3; 12 mg/m 2 mitoxantrone on days 2 and 3) followed by allogeneic stem cell transplantation from an HLA-compatible sibling donor. This patient had a pretreatment CDX2 expression level of 4,202. However, CDX2 transcripts were undetectable after the first course of chemotherapy, and RQ-PCR results remained negative after the second course of ICE, after consolidation chemotherapy, and during the follow-up period (7 and 16 months from diagnosis, respectively). Patient 2, who had t(8;21)-positive AML, achieved CR after 2 courses of ICE with a partial remission after the first course, remained disease free after 2 courses of HAM, but relapsed 10 months from diagnosis. This patient had a pretreatment CDX2 expression level of 4,810; CDX2 transcript levels were significantly reduced but detectable after 2 courses of ICE (expression level, 377) and after 1 course of HAM (expression level, 42), but were increased at the time of clinical relapse (expression level, 951). In both patients, serial quantification of the leukemia-specific fusion transcript resulting from the chromosomal rearrangement (CBFB-MYH11 and RUNX1-CBFA2T1, respectively) by RQ-PCR showed that CDX2 transcript level correlated with level of expression of the respective fusion transcript (data not shown).
Taken together, these results indicate that CDX2 is aberrantly expressed in the majority of patients with AML and that CDX2 expression correlates with disease burden.
CDX2 expression in MDS, CML, or myeloid leukemia cell lines. CDX2 transcripts were detectable in BMMCs from 2 of 5 patients with MDS. One patient had refractory anemia with excess blasts-2 (RAEB-2; CDX2 expression level, 66), and 1 patient had refractory cytopenia with multilineage dysplasia (CDX2 expression level, 2,334). The latter patient progressed to secondary AML 1 month later, and this transition was accompanied by an increase in the number of CDX2 transcripts (expression level, 8,564) , again demonstrating that CDX2 expression correlates with the size of the leukemic clone. No CDX2 transcripts were detected in 1 patient with refractory anemia, 1 patient with RAEB-1, and 1 patient with RAEB-2.
Of the 10 CML patients who were analyzed in this study, 2 had detectable CDX2 transcripts, 1 in myeloid CML-BP (expression level, 639) and 1 in the accelerated phase (CML-AP; expression
Figure 1
CDX2 expression in AML. CDX2 mRNA levels were measured by RQ-PCR in 170 AML patients from different cytogenetic subgroups, as well as in BMMCs (n = 10), CD34 + cells (n = 3), HSCs (n = 3), CMPs (n = 3), GMPs (n = 3), and MEPs (n = 3) from normal individuals. Circles indicate patients with genomic amplification of the CDX2 locus, as assessed by aCGH and FISH (25) . Bars indicate median values. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] showed that 1 allele was expressed (median proportion of cDNA clones with identical nucleotide sequence, 100%; range, 92%-100%). Monoallelic expression in these cases indicated that the aberrant expression of CDX2 was caused by an acquired cisacting genetic event. In contrast, 1 patient (CDX2 expression level, 49,385) demonstrated expression of both alleles. Analysis of the 2 AML cell lines that had been found to carry an informative SNP (EOL-1 and NB4) showed predominant expression of 1 allele of the CDX2 gene (proportion of cDNA clones with identical nucleotide sequence, 89% and 100%, respectively).
Figure 2
Proliferation of AML cell lines after shRNA-mediated silencing of CDX2 expression. (A) Downregulation of CDX2 expression by shRNA TRCN13684 inhibited proliferation of the CDX2-expressing AML cell lines SKM-1, THP-1, MV4-11, MOLM-14, and NOMO-1. In MONO-MAC-6 cells, shRNA TRCN13684 did not induce efficient CDX2 mRNA knockdown, and there was no effect on cell proliferation. Similarly, treatment with shRNA TRCN13684 had no inhibitory effect in the CDX2-negative cell lines HL-60 and K-562. For each of the 6 CDX2-expressing cell lines, the degree of mRNA knockdown is shown (inset) (SKM-1, 84%; THP-1, 68%; MV4-11, 52%; MOLM-14, 49%; NOMO-1, 23%; MONO-MAC-6, 4%). Experiments were performed in triplicate. Values are represented as mean ± SEM. (B) SKM-1 cells were transduced with a lentiviral vector that coexpresses shRNA TRCN13684 and GFP. Sorted cells (proportion of GFP + cells, 98%) were cultured at a density of 0.5 × 10 6 to 1 × 10 6 /ml, and the GFP + fraction was measured by flow cytometry at the indicated time points. The toxicity of CDX2 knockdown was evidenced by a relative depletion of GFP + cells over time. In contrast, analysis of SKM-1 cells transduced with a GFP-expressing pLKO.1 construct without an shRNA sequence (proportion of GFP + cells, 95%) showed no decrease in the percentage of GFP + cells. The degree of CDX2 mRNA knockdown is shown (inset; 93%).
We next tested the hypothesis that monoallelic expression could be attributed to mutations in cis-acting regulatory elements. DNA sequence analysis of a predicted CDX2 promoter region, spanning 687 nucleotides 5' of the annotated transcription start site (TSS) and the first 276 nucleotides of CDX2 exon 1 (Supplemental Figure 2A) , in the 6 patients and 2 cell lines that showed monoallelic expression identified no mutations.
To examine whether the aberrant expression of CDX2 in AML could be caused by gene-specific promoter hypomethylation, a pathogenetic event that has been described in several solid tumors (26) (27) (28) (29) (30) , we studied DNA methylation over a 347-bp region (nucleotide positions -193 to +154 relative to the CDX2 TSS) within a previously described (31) CpG island upstream of CDX2 exon 1 by sodium bisulfite sequencing (Supplemental Figure 2A) . As shown in Supplemental Figure 2B , the CDX2 promoter region was predominantly unmethylated in BMMCs from 3 CDX2-expressing patients (expression levels, 1,101, 1,288, and 2,963, respectively). However, a very similar pattern was observed in BMMCs from 3 CDX2-negative AML patients and PBMCs and granulocytes from 2 healthy individuals without detectable CDX2 expression.
To test the less likely possibility that the aberrant monoallelic expression of CDX2 was related to mutations in the coding sequence of the gene that might affect RNA stability, we sequenced each of the 3 exons of the CDX2 gene in AML patients from different cytogenetic subgroups. No mutations were identified in 32 patients with detectable CDX2 transcripts (median expression level, 697; range, 176-22,477) or 2 patients negative for CDX2 by RQ-PCR.
To determine whether the misexpression of CDX2 was due to gene amplification, we performed RQ-PCR on genomic DNA from 50 AML patients with detectable CDX2 expression (median, 832; range, 39-88,020). Two cases with complex karyotypes that had previously been found to carry extrachromosomal amplification of the CDX2 gene (25), 1 case with pentasomy 13, and 1 case with an isolated marker chromosome showed increased CDX2 copy numbers (78, 11, 5 , and 4, respectively). In contrast, no amplification of the CDX2 locus was present in 18 patients with normal cytogenetics, 1 patient with t(8;21), 3 patients with t(9;11), 5 patients with t(15;17), 7 patients with inv(16), 7 patients with complex karyotypes, or 5 patients with other chromosome aberrations. Taken together, these findings suggest that dysregulated CDX2 expression in AML is frequently monoallelic and that the genetic events that contribute to monoallelic expression are not attributable to locus-specific amplification and lie outside the coding sequence or predicted proximal promoter sequences in the majority of cases.
Growth inhibition of AML cell lines following knockdown of CDX2. To assess the functional significance of aberrant CDX2 expression in myeloid leukemias, we used lentivirus-mediated short hairpin RNA (shRNA) delivery for long-term silencing of CDX2 in human AML cell lines.
We first validated the CDX2 shRNA constructs. Transduction of the NB4 cell line with a pool of 3 shRNA constructs targeting CDX2 resulted in a 58% mRNA decrease as compared with the nonsilencing control construct after 13 days (data not shown), and analysis of individual shRNA constructs showed that shRNA TRCN13684 exhibited the most potent effect (86% mRNA knockdown), followed by TRCN13685 (56%) and TRCN13683 (48%) (Supplemental Figure 3A) . Knockdown analysis 28 days after infection gave similar results, indicating stable downregulation of CDX2 expression (Supplemental Figure 3A) . Immunoprecipitation showed that shRNA-mediated suppression of CDX2 mRNA was associated with greatly diminished levels of CDX2 protein (Supplemental Figure 3B) .
We then investigated the effect of CDX2 silencing in the 6 AML cell lines with CDX2 expression levels between 27 and 344; that is, MOLM-14, THP-1, NOMO-1, MONO-MAC-6, MV4-11, and SKM-1. In all of these 6 cell lines except MONO-MAC-6, silencing of CDX2 expression by shRNA TRCN13684 (mRNA knockdown between 23% and 84%) inhibited cell proliferation as compared with the nonsilencing control construct (Figure 2A ). Highly similar phenotypic effects were exerted by shRNA TRC13685 (Supplemental Figure 4A ). In contrast, exposure of MONO-MAC-6 cells to shRNA TRCN13684 did not induce efficient silencing of CDX2 expression (4% mRNA knockdown), and there was no effect on cell proliferation. Likewise, we found no inhibitory effect of shRNA TRC13684 in HL-60 and K-562 cells, which have no detectable CDX2 expression (Figure 2A) .
To confirm and extend these results, we established a second toxicity assay that allowed us to follow the fate of cells acutely transduced with anti-CDX2 shRNA over time. We created variants of pLKO.1-TRCN13684 and the nonsilencing control construct in which the puromycin resistance gene was replaced with GFP and used lentiviruses prepared from these vectors to infect SKM-1 cells. After lentiviral transduction, GFP-sorted cells were cultured, and the proportion of GFP + cells was monitored by flow cytometry for 24 days. As shown in Figure 2B , the GFP + fraction decreased over time in cells transduced with shRNA TRCN13684, indicating a toxic effect of CDX2 knockdown, whereas no toxicity was observed in cells transduced with the nonsilencing control construct.
Taken together, these results indicate that aberrant expression of CDX2 contributes to the growth potential of myeloid leukemia cells.
Reduced clonogenicity of AML cell lines following knockdown of CDX2. We next tested the ability of AML cell lines transduced with shRNA TRCN13684 to form colonies in clonogenic methylcellulose assays. For the 5 CDX2-expressing cell lines SKM-1, MV4-11, THP-1, MOLM-14, and NOMO-1, we observed a sig- Figure 3C ) after mRNA knockdown as compared with cells transduced with the nonsilencing control construct. In contrast, transduction with shRNA TRCN13684 did not reduce colony formation of EOL-1, which had a very high CDX2 expression level (37,388; 82% mRNA knockdown; estimated residual expression level, 6,730; Figure 3 , A and D); MONO-MAC-6, in which CDX2 expression was not efficiently silenced (4% mRNA knockdown; Figure 3, A and D) ; or HL-60 and K-562, which do not express CDX2 mRNA (Figure 3, A and B) . Transduction of selected cell lines with shRNA TRC13685 confirmed that the observed effects could be attributed to knockdown of CDX2 expression (Supplemental Figure 4, B and C) .
These results support the hypothesis that aberrant expression of CDX2 is involved in the activation of pathways responsible for the increased proliferative and clonogenic capacity that is characteristic of AML.
Increased serial replating activity of primary murine BM and committed hematopoietic progenitor populations expressing Cdx2. As an in vitro test of the effect of Cdx2 on self-renewal properties of primary hematopoietic cells, we initially examined the serial replating ability of pri-
Figure 5
Mouse model of aberrant Cdx2 expression. (A) Mice transplanted with BM cells expressing Cdx2 (n = 5) developed AML after a median of 187 days after transplantation, whereas mice transplanted with MSCV-IRES-GFP-transduced BM (n = 3) showed no evidence of disease with a follow-up duration of more than 250 days (P = 0.013). Secondary recipients (n = 5) transplanted with BM from primary leukemic mice developed AML after a median of 52 days after transplantation. BMT, BM transplantation. (B) Diseased mice showed elevated wbc counts (primary recipients versus control mice, P = 0.09; secondary recipients versus control mice, P = 0.019) and splenomegaly (primary recipients versus control mice, P = 0.0029; secondary recipients versus control mice, P < 0.0001). Values are represented as mean ± SD. (C) Microscopic analysis of PB from primary and secondary leukemic animals demonstrated leukocytosis consisting of frequent immature myeloid cells with a high proportion of blast forms that extensively involved the BM, liver, and spleen. Panels display Wright-Giemsa-stained PB smears and H&E-stained tissue sections from representative mice transplanted with BM cells expressing Cdx2. Original magnification, ×400 and ×1,000 (PB); ×100 and ×600 (BM and liver); and ×40 and ×600 mary unfractionated murine BM transduced with Cdx2 in methylcellulose cultures in the absence of stroma. As shown in Figure 4A , Cdx2-expressing cells demonstrated replating potential to the fourth round of replating, whereas cells transduced with empty vector had a finite ability to serially replate. Cells derived from the fourth replating could subsequently be continuously propagated in liquid culture in the presence of IL-3 ( Figure 4B ) and exhibited morphologic and immunophenotypic characteristics of immature myeloid cells (Figure 4, C and D) .
It has recently been demonstrated that certain leukemia-associated fusion proteins, such as MLL-ENL, MLL-AF9, or MOZ-TIF2, may confer properties of self-renewal to hematopoietic progenitor populations that are committed toward differentiation (32) (33) (34) (35) . As shown in Figure 4 , E and F, expression of Cdx2 in CMPs, GMPs, and MEPs, as well as HSCs, also resulted in serial replating and continuous growth in IL-3-supplemented liquid culture. In contrast, stem and progenitor cells transduced with empty vector showed limited serial replating activity.
Collectively, these findings suggest that aberrant expression of Cdx2 promotes self-renewal properties in primary hematopoietic cells.
Induction of AML in a mouse model of aberrant Cdx2 expression. To assess the leukemogenic potential of Cdx2 in vivo, we performed a murine BM transplantation assay. Mice transplanted with BM cells expressing Cdx2 (n = 5) developed AML after a median of 187 days after transplantation, whereas mice transplanted with MSCV-IRES-GFP-transduced BM cells (n = 3) showed no evidence of disease with a follow-up duration of more than 250 days (P = 0.013; Figure 5A and Supplemental Figure 5 ). The disease was characterized by an elevated wbc count ( Figure 5B, right panel) , the presence of frequent blasts in the peripheral blood (PB) ( Figure 5C ), and marked splenomegaly ( Figure 5B, left panel) . Histopathologic analysis showed extensive infiltration of BM, liver, and spleen by a prominent atypical population of immature myeloid cells and blast forms ( Figure 5C ). Figure 5D ). Southern blot analysis confirmed proviral integration and demonstrated that Cdx2-induced primary leukemias were clonal or oligoclonal (Supplemental Figure 6 ). The leukemia generated was transplantable to secondary recipients (n = 5), resulting in a similar phenotype after a median of 52 days after transplantation ( Figure 5, A-D) . The disease could be categorized as AML without maturation according to the Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice (36) and had similarities to the M0 or M1 subtypes of the French-American-British classification of human AML and to the broad category "AML, not otherwise categorized; subcategories AML, minimally differentiated/AML without maturation" of the current WHO classification (37) .
These observations demonstrated the transforming capacity of aberrant Cdx2 expression in the hematopoietic compartment in vivo.
Dysregulation of Hox gene expression in primary murine hematopoietic cells expressing Cdx2. Several lines of evidence show that Hox genes
are direct transcriptional targets of Cdx2 during development (6, 38, 39) . To determine whether Cdx2-induced leukemogenesis was associated with dysregulation of Hox genes, we used RQ-PCR to quantify the expression of 8 Hox family members (Hoxa6, Hoxa7, Hoxa9, Hoxa10, Hoxb3, Hoxb6, Hoxb8, and Hoxc6) in primary murine hematopoietic stem and progenitor cells transduced with Cdx2 as well as in Cdx2-transduced leukemic cells derived from secondary BM transplant recipients.
Assuming that most genetic alterations responsible for the development of AML occur at the level of normal HSCs or myeloid progenitors, we first measured Hox gene expression in immature, c-Kit + Lin -murine BM cells expressing Cdx2. As compared with cells transduced with empty vector, c-Kit + Lin -cells expressing Cdx2 demonstrated an approximately 25-fold upregulation of Hoxb8. In contrast, Cdx2-transduced cells showed decreased expression of Hoxa10, whereas there were no substantial changes in mRNA levels of Hoxa6, Hoxa7, and Hoxa9. No expression was detected for Hoxb3, Hoxb6, and Hoxc6 in Cdx2-transduced cells or in cells transduced with empty vector ( Figure 6A ).
Figure 6
Hox gene expression in murine hematopoietic cells expressing Cdx2. Figure 6B) .
These results were consistent with the hypothesis that Cdx2-induced leukemogenesis is mediated, at least in part, through altered expression of specific Hox family members.
Discussion
We have found that the caudal-type homeobox gene CDX2 is aberrantly expressed in the leukemic cells of most patients with AML. Ectopic expression of full-length CDX2 in AML was first described by Chase et al., who reported that CDX2 transcripts, as detected by single-round RT-PCR, were present in a single patient with a rare subtype of the disease characterized by the presence of t(12;13)(p13;q12), but not in AML cases without cytogenetic evidence of chromosome 13 abnormalities (23). In our study, which was based on 170 AML cases, we used RQ-PCR for the detection of CDX2 mRNA. It is most likely that differences in the sensitivities of the respective PCR assays account for the disparity between our findings and previous observations.
The mechanisms underlying aberrant expression of CDX2 are not yet fully understood. We observed monoallelic expression of CDX2 in the majority of cases in which there were informative SNPs in the CDX2 coding region, suggesting the presence of acquired alterations in cis-acting regulatory sequences that directly affect the transcription of a single CDX2 allele. These findings are similar to those reported for ectopic expression of the TAL1 gene in T cell acute lymphoblastic leukemia (T-ALL), which has been shown to be monoallelic in a proportion of patients without detectable TAL1 rearrangements (40, 41) . However, as for most cases of T-ALL associated with monoallelic expression of TAL1, we found no mutations in the CDX2 coding region or in the predicted CDX2 promoter sequence, and there was no evidence for gene-specific hypomethylation of the CDX2 promoter. Furthermore, we detected no increase in the CDX2 gene copy number in the majority of cases. Taken together, these results suggest that there are acquired mutations in as-yet-undefined regulatory sequences that account for monoallelic CDX2 expression in most cases of AML.
Two observations indicate that there is a causal relationship between aberrant CDX2 expression and myeloid leukemogenesis. First, selective knockdown of CDX2 in a panel of human AML cell lines exhibiting CDX2 transcript levels in a range similar to that observed in many primary AML samples inhibited proliferation and colony formation of AML cells in vitro. This finding indicates that aberrant expression of CDX2 in hematopoietic progenitors contributes to the enhanced proliferative and clonogenic capacity that is characteristic of human AML. Second, and consistent with a previous report (24) , murine hematopoietic progenitor cells transduced with Cdx2 generated a fully penetrant AML in BM transplant recipients, demonstrating the leukemogenic potential of Cdx2 in vivo.
CDX2 may contribute to AML pathogenesis through dysregulation of HOX genes. Dysregulated HOX gene expression in AML may be caused by chimeric oncoproteins involving MLL (42) or rare chromosomal translocations directly affecting individual HOX genes (43) (44) (45) . The leukemogenic potential of aberrant HOX gene expression mediated by mutant MLL (46) (47) (48) (49) (50) or HOX fusion genes (51, 52) has been well described in various model systems. However, there is also evidence for widespread misexpression of HOX family members in other AML subtypes (53) (54) (55) (56) (57) (58) (59) (60) (61) , suggesting the involvement of as-yet-unknown upstream regulators of HOX gene expression. Like the present report, these studies have demonstrated aberrant increases as well as decreases in the level of HOX gene expression. Cdx2 regulates Hox gene expression during embryogenesis and developmental hematopoiesis, suggesting the hypothesis that aberrant expression of CDX2 in the adult hematopoietic compartment may be associated with altered expression of HOX genes. In support of this hypothesis, we found that expression of Cdx2 in primary murine hematopoietic cells resulted in dysregulation of specific Hox family members that have been implicated in leukemogenesis in other contexts. Most notably, we observed a more than 25-fold increase in expression of Hoxb8 in early myeloid progenitors following transduction with Cdx2, and the leukemic cells from secondary BM transplant recipients showed an approximately 3-fold upregulation of Hoxb6. Ectopic expression of HOXB8 inhibits the induction of granulocytic differentiation in various cell line models (62) , and mice that express Hoxb8 in the hematopoietic compartment show enhanced self-renewal of immature myeloid progenitors and develop a rapid, transplantable myeloid leukemia (63, 64) . Similarly, overexpression of HOXB6 in murine BM enhances the self-renewal of myeloid precursors in vitro and causes AML in vivo (65) . Taken together, these results, in combination with previously reported definitive genetic data that Hox genes are direct transcriptional targets of Cdx2 during development (6, 38, 39) , indicate that the mechanism(s) through which CDX2 contributes to myeloid leukemogenesis could involve deregulation of HOX family members. The observed differences in Hox gene expression between myeloid progenitor cells immediately after retroviral transduction and Cdx2-induced murine leukemias may reflect the cooperative effect of secondary mutations or cell-nonautonomous effects of the BM microenvironment in leukemic cells. Alternatively, there may be differential requirements for deregulation of distinct HOX family members at the onset and during progression of AML.
AML is a genetically and phenotypically heterogeneous disease. Nevertheless, data support the existence of a subpopulation of rare leukemic stem cells that are responsible for initiating and maintaining the disease in most, if not all, AML subtypes (66) (67) (68) . Importantly, these cells have an increased capacity to self renew, and quantitative differences in the self-renewal potential of individual AML stem cells form the basis for a hierarchical organization of the AML stem cell compartment (69) . Our observation that nearly all cases of AML are characterized by aberrant CDX2 expression raises the possibility that CDX2 is part of a common effector pathway that lies downstream of different primary leukemogenic events. An essential role has been demonstrated for Cdx2 in self-renewal of trophoblast stem cells (9) , and 2 other Cdx family members, Cdx1 and Cdx4, are direct targets of the canonical Wnt pathway (70) (71) (72) (73) that has been linked to increased self-renewal in myeloid leukemias (74) (75) (76) (77) . Based on these observations, it is tempting to speculate that in AML, different pathways of transformation converge to enhance self-renewal and that CDX2 may be a component of this shared program. In support of this hypothesis, we found that transduction of primary murine BM and individual committed progenitor populations with Cdx2 conferred serial replating activ-ity, an in vitro surrogate for self-renewal potential (32) (33) (34) (35) 74) , and resulted in a transplantable AML in vivo. To further assess the relevance of CDX2 for self-renewal in human AML, it will be of interest to precisely determine the hematopoietic progenitor population(s) in which CDX2 is expressed and to study its effects in primary leukemic cells using in vivo experimental systems.
In conclusion, our results demonstrate that aberrant expression of the homeotic gene CDX2 in the hematopoietic compartment is a common and functionally relevant event in AML pathogenesis that appears to enhance the self-renewal activity and leukemogenic potential of myeloid progenitor cells. These findings also support the hypothesis that aberrant expression of CDX2 contributes to the dysregulated HOX gene expression that is observed in most cases of AML.
Methods
Patient samples and controls. We analyzed mononuclear cells prepared from diagnostic BM or PB samples from 170 adult patients with AML. All specimens were karyotyped by chromosome banding and FISH (78) . In addition, we studied BMMCs from 5 patients with MDS and BMMCs or PBMCs from 10 patients with CML. As controls, we analyzed BMMCs (n = 10), CD34 + cells (n = 3), HSCs (n = 3), CMPs (n = 3), GMPs (n = 3), and MEPs (n = 3) from normal individuals. The diagnosis of AML or MDS was made according to the WHO classification of hematologic malignancies. The study was approved by the institutional review board of the University Hospital of Ulm, and all patients and volunteers gave informed consent according to the Declaration of Helsinki. Seven of the 10 normal BMMC samples and the 3 normal BM samples that were used for isolating HSCs, CMPs, GMPs, and MEPs were purchased from AllCells.
Flow cytometry and sorting of human hematopoietic stem and progenitor cells. Human HSCs, CMPs, GMPs, and MEPs were isolated from BM as reported previously (73, 79) . Briefly, BMMCs were enriched for CD34 + cells using immunomagnetic beads (Miltenyi Biotec). CD34 + cells were then stained with TRI-COLOR-conjugated antibodies against lineage antigens (CD2, CD3, CD4, CD7, CD8, CD10, CD11b, CD14, CD19, CD20, CD56, CD235a), APC-conjugated anti-CD34, biotinylated anti-CD38 followed by streptavidin-APC-Cy7, FITC-conjugated anti-CD45RA, PE-conjugated anti-CD123, and propidium iodide. Viable HSCs (Lin -CD34 + CD38 -), CMPs (Lin -CD34 + CD38 + CD123 low CD45RA -), GMPs (Lin -CD34 + CD38 + CD123 low CD45RA + ), and MEPs (Lin -CD34 + CD38 + CD123 -CD45RA -) were sorted using a BD FACSAria cell sorter (BD Biosciences) (Supplemental Figure 7) . DNA isolation, RNA isolation, and cDNA synthesis. Genomic DNA was isolated using the DNAzol reagent (Invitrogen). Total RNA from BMMCs and PBMCs or leukemia cell lines was isolated using the RNeasy Mini Kit (QIAGEN) and reverse transcribed (2 μg in a reaction volume of 30 μl) using the TaqMan Gold RT-PCR Kit (Applied Biosystems). Total RNA from sorted stem and progenitor cells was isolated according to the RNeasy Micro protocol (QIAGEN) and analyzed directly by RQ-PCR using the TaqMan One-Step RT-PCR Master Mix (Applied Biosystems).
Quantification of CDX2 expression. Quantification of CDX2 expression was performed by RQ-PCR with primers CDX2 RQ-F (5'-GCGGAACCTGT-GCGAGTG-3') and CDX2 RQ-R1 (5'-GACTGTAGTGAAACTCCTTCTC-CAGC-3') and a 6-carboxy-fluorescein-labeled probe (5'-FAM-CCG-GCGCAGCAGTCCCTCG-3'). For normalization, the porphobilinogen deaminase (PBGD) gene was used according to the following formula: CDX2 copy number / PBGD copy number × 10 5 . CDX2 and PBGD expression levels in patient samples and cell lines were determined by absolute mRNA quantification using plasmid standard curves. Plasmids were generated by cloning PCR products into the pCR4-TOPO vector (Invitrogen). The efficiency of RNAi-mediated knockdown of CDX2 expression was determined by relative mRNA quantification using the ΔδCt method. Reactions were run in duplicate with 2.5 μl cDNA in a total reaction volume of 25 μl using an ABI Prism 7700 Sequence Detection System (Applied Biosystems).
Allelic expression analysis. Partial amplification of the CDX2 gene from cDNA (2 μl) and direct sequencing of amplification products were performed using primers CDX2 cDNA-F (5'-CGGAGGAAAGCCGAGCTA-3') and CDX2 cDNA-R (5'-CTTTGGCTTCCGCAGTGTAA-3'). Amplification products were also cloned into the pCR4-TOPO vector (Invitrogen), and cloned fragments were sequenced with M13 forward and reverse primers.
Sequence analysis of the CDX2 promoter. The location of the CDX2 promoter was predicted using the Gene2Promoter software program (Genomatix). Amplification of the putative promoter sequence from genomic DNA (20 ng) and direct sequencing of amplification products were performed with primers CDX2 promoter 1-F (5'-GTGGTAACCGCCGTAGTCC-3'), CDX2 promoter 1-R (5'-GAGGGGTTGTGCGTAGAGTG-3'), CDX2 promoter 2-F (5'-CACAGACACCAATGGTTGGA-3'), and CDX2 promoter 2-R (5'-GCCTGAATCTAGGATCATAATTTGT-3').
Sodium bisulfite sequencing. Bisulfite treatment of genomic DNA (1 μg) was performed using the CpGenome Fast DNA Modification Kit (Chemicon International). Partial amplification of the CpG island in the CDX2 promoter region from bisulfite-modified DNA (50 ng) was performed using primers CDX2 bDNA-F (5'-GAAGTTTTTAATTATTGGTGTTTGTGTT-3') and CDX2 bDNA-R (5'-AAACCTCACCATACTACCTAAAAACC-3') (31). Amplification products were cloned into the pCR4-TOPO vector (Invitrogen), and cloned fragments were sequenced with M13 forward and reverse primers.
Sequence analysis of the CDX2 coding region. Amplification of CDX2 exons from genomic DNA (20 ng) was performed using primers CDX2 exon 1-F (5'-AGGCCCCCGAATTTGTCT-3'), CDX2 exon 1-R (5'-CACTCGTTAAT-CACGGAAGG-3'), CDX2 exon 2-F (5'-CCCTGCAGCCAGATTTTCTA-3'), CDX2 exon 2-R (5'-GACTGATGGGCTGCCTTG-3'), CDX2 exon 3-F (5'-GAATTTTCCAAATCAGCTTGC-3'), and CDX2 exon 3-R (5'-GCTG-GAGCAGAAGATGTTGAT-3'). Amplification products were sequenced with primers CDX2 exon 1-F, CDX2 exon 1-S1 (5'-GTGGTGCGGATG-GTAGTCTG-3'), CDX2 exon 1-S2 (5'-CACGGAGCTAGGGTACATGC-3'), CDX2 exon 2-F, CDX2 exon 2-R, CDX2 exon 3-F, CDX2 exon 3-S1 (5'-GCTCTGGTGACAGGCTCTCT-3'), and CDX2 exon 3-S2 (5'-GGAG-GCTTTCTGTCTCCTCA-3').
Measurement of CDX2 gene copy number. CDX2 gene copy numbers were measured by RQ-PCR with primers CDX2 RQ-F and CDX2 RQ-R2 (5'-CCAAGCACCCTCCGAAGG-3') and the probe that was used for quantification of CDX2 expression. The coagulation factor VIII gene was used as a reference locus as previously described (80) . Reactions were run in duplicate with 50 ng genomic DNA in a total reaction volume of 25 μl using an ABI Prism 7700 Sequence Detection System (Applied Biosystems).
RNAi VSV-G-pseudotyped lentiviral particles were produced by cotransfection of 293T cells with pLKO.1 constructs and the compatible packaging plasmids pMD.G and pCMVΔR8.91 (83) (84) (85) . Transfections were carried out using FuGENE 6 (Roche Diagnostics), and virus was harvested at 48 and 72 hours after transfection.
Lentiviral supernatants were used to transduce cells in the presence of 8 μg/ml Polybrene (American Bioanalytical), and infected cells were selected with 2 μg/ml puromycin (Sigma-Aldrich).
Immunoprecipitation and Western blotting. Immunoprecipitation was performed as described previously (86) using monoclonal anti-CDX2 (BioGenex). Immunoprecipitated proteins were separated by electrophoresis and transferred to nitrocellulose membranes for Western blotting with anti-CDX2 using standard procedures.
Colony-forming assays. Leukemia cell lines (1 × 10 3 to 1 × 10 4 cells) were plated in methylcellulose medium (MethoCult H4236; StemCell Technologies), and colonies were counted after 10 days.
DNA constructs, retrovirus production, and infection of primary murine hematopoietic cells. The Cdx2 cDNA (GenBank accession number NM_007673) was cloned into the MSCV-IRES-GFP and MSCV-PGK-neo retroviral vectors, and full-length protein expression was documented by Western blotting. Generation of retroviral supernatants and infection of primary murine hematopoietic cells were performed as described previously (87) . For demonstration of proviral integration, genomic DNA prepared from spleen cells of leukemic mice was digested with EcoRI and subjected to Southern blot analysis according to standard protocols.
Serial replating assays and generation of IL-3-dependent myeloid cell lines. Replating experiments were performed as described previously (33) . Briefly, either whole BM was isolated from 5-fluorouracil-treated BALB/c mice or stem and progenitor cell populations were double sorted from C57BL/6 mice as previously described (33) using a BD FACSAria cell sorter (BD Biosciences). Cell populations were transduced with MSCV-Cdx2-PGK-neo or MSCV-PGK-neo. Transduced cells (1 × 10 4 ) were plated in methylcellulose medium (MethoCult M3434; StemCell Technologies) and selected for G418-resistant cells in the first plating. Colonies were counted after 5-7 days, and secondary, tertiary, and quaternary colony formation were analyzed by replating 1 × 10 4 cells obtained by harvesting primary, secondary, or tertiary cultures, respectively. Excess cells from the fourth plating were continuously propagated in RPMI-1640 supplemented with 20% FBS and 10 μg/ml IL-3 (R&D Systems) as described previously (33) .
Murine BM transplantation assay. Transplantation experiments were performed as described previously (33, 88) . For primary transplants, 1 × 10 6 BM cells isolated from BALB/c mice were transduced with MSCV-Cdx2-IRES-GFP or MSCV-IRES-GFP and injected into lethally irradiated (2 × 450 cGy) syngeneic recipient mice. For secondary transplants, 1 × 10 6 BM cells from primary leukemic animals were injected into sublethally irradiated (450 cGy) recipient mice. Diseased animals were sacrificed, spleen and liver weights and wbc counts were recorded, and histopathologic and flow cytometric analyses of murine tissues were performed as described previously (86, 87) . Expression of Cdx2 in leukemic mice was confirmed by detection of Cdx2 mRNA in spleen cells by RQ-PCR ( Figure 6B) . Approval for the use of animals in this study was granted by the Children's Hospital Boston Animal Care and Use Committee under protocol number A04-03-029.
Quantification of Hox gene expression in primary murine hematopoietic cells. For quantification of Hox gene expression in vitro, primary BM cells from C57BL/6 mice were enriched for immature hematopoietic progenitors (c-Kit + Lin -) and transduced with MSCV-Cdx2-IRES-GFP or MSCV-IRES-GFP. After 48 hours, GFP + cells were sorted, and total RNA was isolated and cDNA prepared. For quantification of Hox gene expression in vivo, spleen cells were obtained from secondary BM transplant recipients, and total RNA was isolated and cDNA prepared. Expression levels of Hoxa6, Hoxa7, Hoxa9, Hoxa10, Hoxb3, Hoxb6, Hoxb8, and Hoxc6 were determined by RQ-PCR as described previously (89) .
Statistics. Survival analysis was performed using the Kaplan-Meier method. Differences between survival distributions were analyzed using the logrank test. The difference in CDX2 expression levels between cytogenetic subgroups was evaluated using the Kruskal-Wallis test. All other statistical analyses were performed using the unpaired Student's t test. A P value of less than 0.05 was considered significant. Statistical computations were performed using GraphPad Prism version 4.0c (GraphPad Software).
